Work

Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide

Year: 2005
Type: article
Abstract: IN BRIEF Therapies based on the incretin hormone glucagon-like peptide 1 are novel treatment options for type 2 diabetes that act through a variety of complementary mechanisms. Exenatide, which will likely become the first application to reach the market, has shown promise in phase III trials in reducing hemoglobin A1c without causing significant hypoglycemia or weight gain.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2150388129
FWCI: 2.163
Cites: 63
Cited by: 55
Related to: 9